Case-based review: Craniopharyngioma treated with intracystic peginterferon.
[BACKGROUND] Craniopharyngiomas are benign tumors with a challenging management due to the excessive morbidity of the classical therapeutic approaches.
APA
Salagre GN, Iglesias S, et al. (2025). Case-based review: Craniopharyngioma treated with intracystic peginterferon.. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 41(1), 402. https://doi.org/10.1007/s00381-025-07070-2
MLA
Salagre GN, et al.. "Case-based review: Craniopharyngioma treated with intracystic peginterferon.." Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, vol. 41, no. 1, 2025, pp. 402.
PMID
41348206
Abstract
[BACKGROUND] Craniopharyngiomas are benign tumors with a challenging management due to the excessive morbidity of the classical therapeutic approaches. This has led to the current trend of a multimodal approach with more conservative surgical options.
[CASE REPORT] We present the case of a 6-year old patient diagnosed with a giant multicystic and rapidly recurrent craniopharyngioma, showing the current trends towards a multimodal therapeutic approach with less aggressive surgical options. We emphasize the use of two different intracystic cycles of a new formulation of pegylated 2a interferon. We make a review of the available literature focusing on historical and current treatment options.
[CONCLUSION] Craniopharyngiomas remain a challenge due to the morbidity caused by both the disease and its treatment. The current trend towards a more conservative approach has many alternative treatment options, with intracystic pegyladed 2a interferon being a safe and effective choice, even in consecutive administrations.
[CASE REPORT] We present the case of a 6-year old patient diagnosed with a giant multicystic and rapidly recurrent craniopharyngioma, showing the current trends towards a multimodal therapeutic approach with less aggressive surgical options. We emphasize the use of two different intracystic cycles of a new formulation of pegylated 2a interferon. We make a review of the available literature focusing on historical and current treatment options.
[CONCLUSION] Craniopharyngiomas remain a challenge due to the morbidity caused by both the disease and its treatment. The current trend towards a more conservative approach has many alternative treatment options, with intracystic pegyladed 2a interferon being a safe and effective choice, even in consecutive administrations.
MeSH Terms
Humans; Craniopharyngioma; Pituitary Neoplasms; Interferon-alpha; Child; Polyethylene Glycols; Recombinant Proteins; Male; Antineoplastic Agents; Magnetic Resonance Imaging